Retatrutide — Buy in Canada

What is Retatrutide?

Retatrutide is a novel triple receptor agonist targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously. It is currently the most potent fat loss and metabolic research peptide available in Canada, offering significantly greater efficacy than dual agonists like Tirzepatide.

Canadian researchers studying metabolic disease, obesity, and energy balance are increasingly investigating Retatrutide for its multi-pathway approach to fat oxidation and appetite suppression. VELTRIDE supplies Retatrutide 10mg at ≥98% HPLC purity with a third-party COA, shipped discreetly across Canada from Kelowna, BC.

Key Research Areas

• Simultaneous GLP-1, GIP, and glucagon receptor activation studies
• Superior fat mass reduction compared to single/dual agonists in preclinical models
• Appetite suppression and reduced food intake research
• Metabolic rate enhancement and energy expenditure studies
• Insulin sensitivity and glycemic control research
• Liver fat reduction and NAFLD/NASH research applications

Retatrutide vs. Tirzepatide vs. Semaglutide

Retatrutide targets three receptor pathways (GLP-1 + GIP + Glucagon), making it more potent in preclinical fat-loss research than Tirzepatide (GLP-1 + GIP dual agonist) or Semaglutide (GLP-1 only). All three are available from VELTRIDE for Canadian research use.